1. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia;Frangoul;N Engl J Med,2021
2. CRISPR Therapeutics. FDA accepts biologics license applications for exagamglogene autotemcel (exa-cel) for severe sickle cell disease and transfusion-dependent beta thalassemia [Internet]. Boston: CRISPR Therapeutics. 2023 Jun 8 [cited 2023 Aug 10]. Available from: https://crisprtx.com/about-us/press-releases-and-presentations/fda-accepts-biologics-license-applications-for-exagamglogene-autotemcel-exa-cel-for-severe-sickle-cell-disease-and-transfusion-dependent-beta-thalassemia.
3. CRISPR Therapeutics. CRISPR Therapeutics provides business update and reports first quarter 2023 financial results [Internet]. Boston: CRISPR Therapeutics. 2023 May 8 [cited 2023 Aug 10]. Available from: https://crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-provides-business-update-and-reports-first-quarter-2023-financial-results.
4. CRISPR use in humans shows promise while experts weigh ethical concerns;Weiss;Engineering,2020
5. Ledford H, Callaway E. Pioneers of revolutionary CRISPR gene editing win chemistry Nobel [Internet]. London: Nature; 2020 Oct 7 [cited 2023 Aug 14] Available from: https://www.nature.com/articles/d41586-020-02765-9.